May 14, 2020
1 min read
Save

VisionCare receives CE mark for implantable telescope delivery system

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A new delivery system for the CentraSight treatment program, which includes a telescope implant for treatment of age-related macular degeneration, has received CE mark, according to a press release from VisionCare.

The Tsert-Si includes a preloaded telescopic implant with foldable haptics that can be delivered through a 6.5-mm incision in patients with end-stage age-related macular degeneration.

In the United States, the CentraSight treatment program is indicated for patients with end-stage AMD “who meet specific eye health and vision requirements, and for whom common treatments such as glasses, vitamins, drugs or cataract surgery will not lead to vision improvement,” the release said.

Treatment is contraindicated in patients who have undergone any intraocular surgery in the affected eye, including cataract surgery, according to the release.